Avoid common mistakes on your manuscript.
To the Editor,
The Nuclear Factors of Activated T cells (NFATs) family of transcription factors comprises 5 proteins (NFAT1-5) essential for T-cell activation [1]. NFAT1-4 proteins function on a calcium–calcineurin dependent signalling cascade which leads to nuclear localization of these transcription factors [2]. Activated calcineurin by downstream T-cell receptor (TCR) signals dephosphorylates NFATs, resulting in binding the interleukin-2 (IL-2) promoter region in the nucleus. The other specific roles of NFAT family members include follicular helper T-cell (Tfh) differentiation, regulation of immunological tolerance, and the immune metabolism and the control mechanism of T-cell anergy and exhaustion [2]. A novel type of syndromic inborn error of immunity has been described recently, caused by biallelic loss-of-function variants in the NFATC2 gene encoding for NFAT1 [3]. Here we identified NFAT1 deficiency caused by a homozygous deletion in NFATC2 gene in a patient with EBV (Epstein-Barr virus)-associated inborn error of immunity.
The index patient is a 12-year-old girl born to first-degree consanguineous parents. She was referred to immunology clinic due to possible recurrent chest infections, lung deterioration, chronic wet cough and failure to thrive at the age of 9. Her elder brother died of lymphoma when he was 5 years old, otherwise family history was unremarkable. Physical examination revealed bilateral crackles on auscultation and generalized lymphadenopathies. In the laboratory findings, severe hypogammaglobulinemia (IgG: 390 mg/dl, IgA: < 10 mg/dl, IgM: 99 mg/dl) together with low vaccine (Anti-HBs: -) and isohemagglutinin responses (Anti-A: ½, Anti-B: ½) were detected. Absolute lymphocyte counts and the main subset distribution of T and B cells were normal in the initial evaluation (Supplementary Table 1). EBV PCR was positive with a high copy number of 1.0 × 106 /ml, prompting a possible diagnosis of EBV-related combined immunodeficiency. Any bacterial, fungal or viral infection agent in sputum or endotracheal aspirate culture were not detected. IVIG (intravenous immunoglobulin) replacement therapy together with trimethoprim-sulfamethoxazole prophylaxis was initiated. Lymph node biopsy showed EBV-related lymphoproliferative disease with EBER antigen positivity and non-suggestive findings of lymphoma. We concluded that EBV-related lymphoproliferation might contribute the development of lung deterioration in the patient. Following 6 months she received acyclovir therapy, however, it was not sufficient to control the EBV copy numbers. Due to lymphadenopathy, lymphoproliferation and malignity risk, four courses rituximab (375 mg/m2) were given. Although the EBV copy numbers were decreased, it was not negative and additional 4 courses rituximab were continued. After the 6. course, EBV infection was eradicated. Due to immunodeficiency, chronic EBV viremia and uncontrolled lymphoproliferation, the patient was planned for allogeneic hematopoietic stem cell transplantation (HSCT) from her healthy HLA-identical sibling. Following a treosulfan/fludarabine conditioning regimen, peripheral stem cells were infused at a dose of 5.7 × 106 CD34 + cells/kg body weight. Post-transplantation thrombocyte, lymphocyte and neutrophil engraftment occurred on days + 10, + 11, and + 12 respectively. Acute skin and gastrointestinal graft versus host disease (GvHD) manifested on posttransplant 2 months which developed into chronic skin and lung GvHD. She was treated with multiple immunosuppressive agents including corticosteroids, ruxolitinib, cyclosporin A, MMF, imatinib as well as mesenchymal stem cells and extracorporeal photopheresis. In the 3rd year after HSCT she retained full donor chimerism, exhibited normal lymphocyte subsets and immunoglobulin levels, and EBV infection did not occur again. However, she suffered from chronic skin and lung GvHD, necessitating a lung transplantation. While she was waiting for a donor, she succumbed to a respiratory failure following a severe Klebsiella sepsis (Fig. 1A).
Given the consanguinity, we performed whole exome sequencing to identify a potential genetic etiology of the disease. Under the assumption of autosomal recessive inheritance, sequencing analysis revealed a homozygous deletion resulting the lack of 2 amino acids in the NFATC2 gene (NM_012340.4, c.340_345delGAGATC, p.Glu114_Ile115del). The variant was validated by capillary sequencing. The father and the healthy brother of the patient were heterozygous for the variant (Fig. 1B), but material from the mother was not available as she had passed away due to breast cancer. The SIFT and Provean prediction scores indicated the variant as damaging and deleterious, respectively and the CADD score was 21. Inherited deletion affects the conserved PxIxIT motif within the calcineurin-binding domain of NFAT1 (Fig. 1C and D).
Detailed lymphocyte subpopulation analysis during rituximab therapy (at the age of 12) revealed CD4 + CD45RA + and CD4 + CD45RO + naive and memory T cells, respectively, were almost equal (49.35% and 49.33%). There was a relative expansion of the CD4+CCR7− effector T-cell subset. Both CD19 + and CD20 + B cells were almost not detectable likely due to rituximab treatment. The percentage and number of NK cells were also diminished (Supplementary Table 1). The expression of NFAT1 and proteins involved in downstream of TCR signalling were normal by western blot (Fig. 1E). To assess the functional responses, we studied activation and proliferation of T cells, which were comparable to healthy controls (Fig. 1F and G). IL-2 production following PMA/Ionomycin stimulation was significantly lower in patient lymphocytes in comparison with the healthy control (Fig. 1H). Cytotoxic killing function of patient’s lymphoblasts was impaired in a target cell killing assay (Fig. 1I).
Since NFAT1 protein has a pleiotropic role in different human cell types, NFAT1 deficiency may affect various pathways in immune cells. Recently, Sharma and colleagues identified complete NFAT1 deficiency in a patient with progressive joint contractures, osteochondromas, and B-cell malignancy [3], caused by a homozygous 4-nucleotide deletion leading a premature stop codon in the NFATC2 gene. The immune phenotype of this patient was remarkable for accumulation of naive B cells, exhausted CD4 + T cells, reduced T follicular helper and CD8 + T cells, in addition to impaired cartilage cell growth and differentiation. In our patient, only CD4 + effector memory cells were increased and unlike the first identified patient, there is no soft tissue or cartilage abnormalities. The variant identified in our study is located in the calcineurin binding site and likely affects the translocation of the NFAT1 protein to the nucleus. Despite the fact that NFATC2 knockout mice model and complete NFAT1 deficiency certified the impaired regulation of chondrogenesis [3, 4], there may be residual NFAT1 function in our patient. This may be the possible explanation for the absence of profound cartilage/joint issues in the patient. Future identification of additional patients harbouring missense variants in NFATC2 will enable a more comprehensive understanding of genotype-phenotype correlations in this rare inborn error immunity.
The differentiation and effector functions of CD8 + T cells regulate by NFAT1 and NFAT2 [5] and the impaired cytotoxicity of CD8 + T cells with diminished IL-2 production have been previously shown in the studies by Klein-Hessling and our own data [6, 7]. We consider that the decreased killing activity is the possible cause of the EBV-associated lymphoproliferation in our patient. In contrast to cytotoxic T lymphocytes, NFAT1 was shown as a negative regulator of NK-cell function in mice [8]. However, progressive decrease of NK-cell numbers in the patient’s follow up might had an additional effect on uncontrolled EBV-associated proliferation. Although IL-2 production via PMA/Ionomycin stimulation was diminished in our patient’s T cells, the activation and proliferation were intact in CD3 + T lymphocytes. We think that these mechanisms could be compensated by NFAT2 [9] or an IL-2 and NFAT independent manner induced by CD28 stimulation [10]. In murine models, NFATC2 knockout (KO) CD4 + CD252 ‘conventional’ T cells displayed increased proliferation after CD3 stimulation [11]. In the same study, generalized lymphadenopathy and B-cell malignancies were developed in NFATC2 KO mice which may explain uncontrolled B cell lymphoproliferation in our patient. Unfortunately, we could not perform detailed functional tests for impaired B-cell development and differentiation due to progressive loss of B lymphocytes after rituximab treatment, and similarly, the allogenic HSCT prevent us from being able to characterize the T-cell compartment in further depth. Notably, although the phenotype of the patient in our study is suggestive that the NFATC2 lesion may be causative for the observed phenotype, the lack of additional primary patient material made it impossible to demonstrate causality of the NFATC2 for the observed clinical and immunological phenotype in a strict sense accordingly to outlined criteria by distinguished investigators in the field [12].
In conclusion, we may have identified an additional patient with an inborn error of immunity linked to a genetic defect in NFATC2. We speculated that, similar to other IEIs, NFAT1 deficiency may present with a spectrum of clinical phenotypes, since NFAT family proteins play different key roles in immune system and the types of the variants may affect the immune mechanisms in different ways cause diverse phenotypes. Hence, several NFAT family variants such as in NFATC1, NFATC2 and NFAT5 genes have been identified with different inborn errors of immunity [3, 7, 13]. Since only two patients have been identified with NFAT1 deficiency so far, more patients with longer follow up are needed to elucidate this rare inborn error of immunity. In addition, HSCT may be considered as a therapeutic strategy since successful immune reconstitution was established with the control of hypogammaglobulinemia and EBV infection in our patient.
Data Availability
There is no dataset generated during the study.
References
Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472–84.
Vaeth M, Feske S. NFAT control of immune function: new frontiers for an abiding trooper. F1000Res. 2018;7:260.
Sharma M, Fu MP, Lu HY, Sharma AA, Modi BP, Michalski C, et al. Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy. Blood. 2022;140(17):1858–74.
Ranger AM, Gerstenfeld LC, Wang JX, Kon T, Bae HS, Gravallese EM, et al. The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. J Exp Med. 2000;191(1):9–21.
Xu T, Keller A, Martinez GJ. NFAT1 and NFAT2 differentially regulate CTL differentiation upon acute viral infection. Front Immunol. 2019;10:184.
Klein-Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Floter J, et al. NFATc1 controls the cytotoxicity of CD8(+) T cells. Nat Commun. 2017;8(1):511.
Kostel Bal S, Giuliani S, Block J, Repiscak P, Hafemeister C, Shahin T, et al. Biallelic NFATC1 mutations cause an inborn error of immunity with impaired CD8+ T-cell function and perturbed glycolysis. Blood. 2023;142(9):827–45.
Rothfelder K, Märklin M, Wild J, Dörfel D, Kanz L, Müller MR, Salih HR. Involvement of NFAT Transcription Factors in NK Cell Reactivity. Blood. 2016;128(22):1344–1344.
Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity. 2001;14(1):13–20.
Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. IL-2-independent activation and proliferation in human T cells induced by CD28. J Immunol. 1999;163(4):1809–16.
May SL, Zhou Q, Lewellen M, Carter CM, Coffey D, Highfill SL, et al. Nfatc2 and Tob1 have non-overlapping function in T cell negative regulation and tumorigenesis. PLoS ONE. 2014;9(6):e100629.
Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211(11):2137–49.
Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, et al. Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015;194(6):2551–60.
Acknowledgements
We would like to thank “Can Sucak Candan Biseyler” Foundation (CSCBF) for their support and contributions during the study. CSCBF was founded in 2018 to honor Can Sucak who lost his life due to complications of primary immunodeficiency. CSCBF supports research in the field of primary immunodeficiency and promotes awareness.
We also thank Alexandra Frohne from Boztug Lab for the preparation of the NFAT1 representation in Figure 1C.
Funding
Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK). The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
B.E and S.K.B performed the experiments. C.A and G.Z.E provided clinical care of the patient and clinical data. B.E, S.K.B and K.B wrote the manuscript. B.E and K.B conceptualized and coordinated the study and provided laboratory resources. All authors critically reviewed the manuscript and agreed to its publication.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics Approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the local Ethics Committee of the Hacettepe University (GO 20/407).
Consent to Participate
Informed consent was obtained from all individual participants included in the study.
Consent for Publication
The authors affirm that the patient provided informed consent for publication of the images of X-Ray and CT scans in the Fig. 1.
Disclosure of Conflicts of Interests
No conflict of interest exists.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Erman, B., Bal, S.K., Aydoğmuş, Ç. et al. A Novel Homozygous Six Base Pair Deletion Found in the NFATC2 Gene in a Patient with EBV-Associated Lymphoproliferation. J Clin Immunol 44, 74 (2024). https://doi.org/10.1007/s10875-024-01675-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10875-024-01675-z